GLP-3 RT (RETATRUTIDE) Description: GLP-3 RT (Retatrutide) is an investigational unimolecular triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR)
That triple mechanism changes everything about how the compound affects appetite, metabolism, and fat oxidation
The three scenarios for compounded semaglutide access post-shortage When the FDA removes semaglutide from the shortage list, compounding pharmacies face three possible paths forward: Scenario 1: Full cessation
Several clinical trials implemented a combination of semaglutide treatments with sulfonylurea, sitagliptin, basal insulin, metformin, or other antidiabetic drugs (Table 3)
The washout should be spent preparing your body, not scrambling for materials
CHS Reports $70M Q4 Loss : Community Health Systems reported a $70 million loss in Q4 2024